Calyxo has raised $122.7M across 1 funding round, plus 2 undated rounds. The company is valued at $684.6M.
Calyxo raised $32.7 million in a Series C financing round to expand its kidney stone treatment technology to more urologists and patients.
1 funding round, the latest highlighted.
Calyxo was founded in 2016, United States.
No date is disclosed for this round.
No filing has been made.
1 dated round, newest first.
No. Calyxo is a private company; its shares do not trade on a public exchange.
The last valuation is $684.6M.
Lead investors for each round are in the funding timeline.
The closest medical devices peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
